PD-1 Blockade and CDK4/6 Inhibition Augment Nonoverlapping Features of T Cell Activation in Cancer

Scientists performed single-cell RNA-sequencing and T cell receptor clonotype tracking of breast and ovarian cancer patients treated with the CDK4/6 inhibitor ribociclib and PD-1 blockade.